Platinum-Resistant Ovarian Carcinoma — Trials

Platinum-Resistant Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

109 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 56
Recruiting: 29
Ph III recruiting: 3
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 52.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07265739	Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer	not yet recruiting	Phase 2	27	Massachusetts General HospitalOTHER	1	Sep 22, 2026	clinicaltrials
NCT07772882	Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer	not yet recruiting	Phase 1	24	Rebecca ArendOTHER	1	Aug 19, 2026	clinicaltrials